NCI Emerging Technologies Seminar - Driving Next Generation Cancer Immunotherapeutic Design Using Partillion Technology
In a presentation for the National Cancer Institute (NCI) emerging technologies seminar series, Partillion Co-Founder Dr. Dino Di Carlo shares how the Nanovial technology being commercialized by Partillion Bioscience, enables scalable selection of functional immune cells, driving next-generation cancer immunotherapeutic design.